Skip to main content

Dr. Temitayo O. Chidi, MD, PHD

Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)

  • Medicare participating

At a glance

Years since graduation
21
In the NPI registry since
2008
Medicare patients seen, 2024
42

Licensed in California since 2019, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2005Medical school: University of Wisconsin School of Medicine
  • 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Neurology with Special Qualifications in Child Neurology Physician primary
    VA license 0101250149 · CA license C166590 (first issued 2019; current)
  • Sleep Medicine (Psychiatry & Neurology) Physician
    CA license C166590 (first issued 2019; current) · DC license MD040137 · MD license D76678 · VA license 0101250149

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Child Neurology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
42
Services billed
81
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes1616

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Zolpidem Tartrate
Other prescribers in Sacramento, CA
19
Mirtazapine
Other prescribers in Sacramento, CA
16

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 10 companies reported 27 payments worth $3,204 in total to this clinician.

By company
Acadia Pharmaceuticals Inc$1,996
Jazz Pharmaceuticals Inc.$431
Axsome Therapeutics, Inc.$224
Neurelis, Inc.$157
Sk Life Science, Inc.$136
Harmony Biosciences LLC$88.18
UCB, Inc.$78.00
Corium, LLC$49.63
By type
Food and Beverage$1,704
Compensation for services other than consulting (speaking, faculty)$1,500

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Dec 3, 2025Acadia Pharmaceuticals Inc
Dec 3, 2025
Compensation for services other than consulting (speaking, faculty)
DAYBUE · RETT SYNDROME
$1,500

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Industry-funded research

Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $86,641 in research payments for these studies, mostly to the institutions running them.

  • Phase 3 multicenter randomized doubleblind group sequential placebocontrolled study to assess efficacy and safety of rimegepant for the treatment of migraine with or without aura in children and adolescents 6 to 18 …
    Pfizer Inc.
  • A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
    Jazz Pharmaceuticals Inc.
  • Phase 3 multicenter openlabel study to assess the longterm safety and tolerability of rimegepant for the acute treatment of migraine with or without aura in children and adolescents 6 to 18 years of age
    Pfizer Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Child Neurology clinicians in Sacramento

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 23, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1295992063. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.